Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.

You may also be interested in...



GSK Retrovir Goes Generic

Zidovudine ANDAs from Ranbaxy, Roxane and Aurobindo are the first generic pediatric AIDS drugs approved for the U.S. market.

GSK Retrovir Goes Generic

Zidovudine ANDAs from Ranbaxy, Roxane and Aurobindo are the first generic pediatric AIDS drugs approved for the U.S. market.

Ranbaxy Files Three Antiretroviral ANDAs Under Expedited Review Process

The generic firm's versions of zidovudine, lamivudine and nevirapine were filed under the President's Emergency Plan for AIDS Relief. The products will only be sold in the developing world; Ranbaxy plans to file a total of 15 ANDAs under the plan by the second quarter.

Related Content

Topics

UsernamePublicRestriction

Register

PS060988

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel